ArticleACS omega2025
N‑Terminal Conjugation of a Near-Infrared Photosensitizer to an Antibody for Cancer Diagnosis and Treatment.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Switchbody, an Antigen-Responsive Enzyme Switch Based on Antibody and Its Working Principle.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We developed immunoprobes by conjugating fluorophores to the N-terminal region of an antibody to detect cancer markers via fluorescence and destruct cancer cells via antigen-dependent photosensitization. To fabricate an immunoprobe for detection, peptides conjugated with fluorophores, such as TAMRA or methylene blue (MB), were ligated at the N-terminus of the heavy chain of trastuzumab (Traz), which is an antibody that recognizes the cancer marker human epidermal growth factor receptor 2 (HER2). The fluorescence intensities of both immunoprobes were decreased upon the addition of HER2 in a dose-dependent manner, which is promising for cancer diagnosis. To achieve antigen-dependent
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.